Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019, with a specific reporting date of October 10, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific equity transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £17.2918 per share.
- Transaction Volume: 14 Ordinary Shares per individual transaction (comprising 7 partnership shares and 7 matching shares).
- Transaction Date: October 9, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It documents routine acquisitions of shares by senior executives and their associates as part of a compensation plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share acquisitions.
Investor Verification Points
- Verify the total number of shares acquired by the listed PDMRs and PCAs to assess aggregate insider buying activity for the period.
- Confirm the alignment of the transaction price (£17.2918) with the market price of GSK ordinary shares on October 9, 2019.
- Review the Company's Share Reward Plan rules to understand the vesting conditions and matching share mechanics for the executives listed (including CEO Emma Walmsley).
- Note that this filing does not provide data on GSK's broader financial performance; refer to Form 20-F or quarterly earnings releases for that information.